COR logo

CENCORA INC

CORNYSE
πŸ† #259 by market capEarnings Nov 3 Β· PostUS Equity
$304.20β–² $0.40 (+0.13%)
Live
πŸ””
Track COR
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 0.1%
7dβ–Ό 3.3%
14dβ–Ό 5.9%
30dβ–Ό 5.5%
ytdβ–Ό 10.0%
1yβ–Ό 1.3%
🏦Market Cap
$59.18B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
+9.3%
Slowing
πŸ“ŠGross Margin
3.7%
Thin
πŸ’΅FCF Margin
1.2%
Thin
βš–οΈP/S Ratio
0.2x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$301.11 – $310.13
52-Week Range
$244.82 – $377.54
Volume
$3.20B
Avg Volume
$3.93B
Shares Outstanding
194.6M
Next Earnings
Nov 1, 2026

Fundamentals Snapshot

Annual Revenue
$321.33B
Last Q Revenue
$84.75B
P/E Ratio
22.5
P/S Ratio
0.2x
EPS (TTM)
$13.59
Dividend Yield
0.79%
Dilution (1yr)
+0.1%

Why Investors Own COR

  • βœ“High-growth profile β€” revenue up +16.6% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 26% gross margin and 15% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

COR logo

CENCORA INC

COR
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$321.3Bβ–² +9.3% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
3.2%β–² +6.6% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$3.6Bβ–² +20.0% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$3.2Bβ–² +7.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
195.3Mβ–² +0.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$6.1Bβ–Ό βˆ’$1.3B YoY
StockOtter Β· stockotter.space

About CENCORA INC

Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.S. Healthcare Solutions segment, the company supplies a broad spectrum of pharmaceutical items, including generic and injectable medications, over-the-counter health products, and home healthcare equipment. Its extensive client network includes acute care hospitals, health systems, a variety of retail and mail-order pharmacies (independent, chain, long-term care), medical clinics, and other healthcare providers. This division also manages the distribution of crucial specialized pharmaceutical products like plasma, blood derivatives, and vaccines. Beyond product supply, Cencora offers comprehensive support services, such as pharmacy management, staffing solutions, and strategic consulting. It develops and implements supply management software, provides packaging services for both institutional and retail healthcare settings, and assists with clinical trial support, post-market approval processes, and commercialization strategies. For biotechnology and pharmaceutical manufacturers, the company delivers data analytics, outcomes research, and other specialized services. Furthermore, Cencora serves the animal health market, providing pharmaceuticals, vaccines, parasiticides, diagnostics, and micro feed ingredients for both companion and production animals. It also offers sales force support to manufacturers and specialized services to medical professionals, particularly oncologists, as well as to hospitals and dialysis clinics. The International Healthcare Solutions division concentrates on global pharmaceutical wholesale activities, associated services, and worldwide commercialization support. It ensures the efficient distribution of medicines, various healthcare goods, and related services to an international customer base comprising pharmacies, doctors, health centers, and hospitals. This segment also delivers specialized transportation and logistics solutions specifically designed for the biopharmaceutical sector. Founded in 1871, the company was formerly known as AmerisourceBergen Corporation before adopting the name Cencora, Inc. in August 2023. Its corporate headquarters are situated in Conshohocken, Pennsylvania.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
21 analysts
Strong Buy5
Buy10
Hold6
Sell0
Strong Sell0
Ratings as of Sep 2026

Latest News & Updates

Business WireΒ·4d ago

Cencora Elects Robert E. Sanchez to Its Board of Directors

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Robert E. Sanchez as a new independent director, effective October 1, 2026. Mr. Sanchez is the Executi

Zacks Investment ResearchΒ·6d ago

Here's Why Cencora (COR) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

MarketBeatΒ·7d ago

Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027

Cencora NYSE: COR executives said the company expects its specialty-focused strategy to support continued growth into fiscal 2027, citing demand in oncology and retina, expanded physician-services capabilities and moment

Defense WorldΒ·8d ago

Cencora Highlights Specialty Growth, MSO Expansion and Walgreens Ties at Conference

Cencora (NYSE: COR) executives highlighted the company's specialty pharmaceutical positioning, medical specialty organization strategy and capital-allocation priorities during an investor conference discussion, while rea

Zacks Investment ResearchΒ·11d ago

Here's Why Cencora (COR) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Defense WorldΒ·12d ago

Corient Private Wealth LP Purchases 19,068 Shares of Cencora, Inc. $COR

Corient Private Wealth LP lifted its holdings in Cencora, Inc. (NYSE: COR) by 102.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,601 s